{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T14:33:39Z","timestamp":1794666819629,"version":"4.9.1"},"reference-count":148,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetol Metab Syndr"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s13098-016-0159-z","type":"journal-article","created":{"date-parts":[[2016,7,27]],"date-time":"2016-07-27T19:29:48Z","timestamp":1469647788000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":147,"title":["Interactions between kidney disease and diabetes: dangerous liaisons"],"prefix":"10.1186","volume":"8","author":[{"given":"Roberto","family":"Pecoits-Filho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Abensur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina C. R.","family":"Bet\u00f4nico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisson Diego","family":"Machado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika B.","family":"Parente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1rcia","family":"Queiroz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Eduardo Nunes","family":"Salles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Titan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Vencio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,7,28]]},"reference":[{"key":"159_CR1","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.2337\/dc14-S014","volume":"37","author":"American Diabetes Association","year":"2014","unstructured":"American Diabetes Association. Standards of care in diabetes 2014. Diabetes Care. 2014;37:S14\u201380.","journal-title":"Diabetes Care"},{"key":"159_CR2","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2337\/db09-9028","volume":"58","author":"Ralph DeFronzo","year":"2009","unstructured":"DeFronzo Ralph. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58:773\u201395.","journal-title":"Diabetes"},{"issue":"Suppl 2","key":"159_CR3","doi-asserted-by":"crossref","first-page":"S155","DOI":"10.2337\/db06-S019","volume":"55","author":"D Porte","year":"2006","unstructured":"Porte D. Central regulation of energy homeostasis. Diabetes. 2006;55(Suppl 2):S155\u201360.","journal-title":"Diabetes"},{"key":"159_CR4","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/35007534","volume":"404","author":"MW Schwartz","year":"2000","unstructured":"Schwartz MW, Woods SC, Porte D, Seeley RJ, Baskin DC. Central nervous system control of food intake. Nature. 2000;404:661\u201371.","journal-title":"Nature"},{"key":"159_CR5","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1172\/JCI29063","volume":"116","author":"L Plum","year":"2006","unstructured":"Plum L, Belgardt BF, Bruning JC. Central insulin action in energy and glucose homeostasis. J Clin Invest. 2006;116:1761\u20136.","journal-title":"J Clin Invest."},{"key":"159_CR6","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/0026-0495(90)90002-T","volume":"39","author":"RC Bonadonna","year":"1990","unstructured":"Bonadonna RC, Groop L, Kraemer N, Ferrannini E, Del Prato S, DeFronzo RA. Obesity and insulin resistance in humans: a dose-response study. Metabolism. 1990;39:452\u20139.","journal-title":"Metabolism."},{"key":"159_CR7","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1172\/JCI10583","volume":"106","author":"GI Shulman","year":"2000","unstructured":"Shulman GI. Cellular mechanisms of insulin resistance. J Clin Invest. 2000;106:171\u20136.","journal-title":"J Clin Invest."},{"key":"159_CR8","first-page":"6","volume":"3","author":"EB Parente","year":"2014","unstructured":"Parente EB, Pereira PHGR, Nunes VS, Lottenberg AMP, Lima CSLM, Rochitte CE, et al. The effects of high-fat or high-carbohydrate diet on intramyocellular lipids. J Food Nutr Disord. 2014;3:6.","journal-title":"J Food Nutr Disord."},{"key":"159_CR9","first-page":"E214","volume":"237","author":"RA DeFronzo","year":"1979","unstructured":"DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol Endocrinol Metab Gastrointest Physiol. 1979;237:E214\u201323.","journal-title":"Am J Physiol Endocrinol Metab Gastrointest Physiol."},{"key":"159_CR10","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00280883","volume":"28","author":"DR Matthews","year":"1985","unstructured":"Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia. 1985;28:412\u20139.","journal-title":"Diabetologia"},{"key":"159_CR11","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.2337\/diacare.22.9.1462","volume":"22","author":"M Matsuda","year":"1999","unstructured":"Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 1999;22:1462\u201370.","journal-title":"Diabetes Care"},{"key":"159_CR12","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1172\/JCI105685","volume":"46","author":"MJ Perley","year":"1967","unstructured":"Perley MJ, Kipnis DM. Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects. J Clin Invest. 1967;46:1954\u201362.","journal-title":"J Clin Invest."},{"key":"159_CR13","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.2337\/diacare.26.10.2929","volume":"26","author":"DJ Druker","year":"2003","unstructured":"Druker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care. 2003;26:2929\u201340.","journal-title":"Diabetes Care"},{"key":"159_CR14","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/35041046","volume":"2","author":"N Ozaki","year":"2000","unstructured":"Ozaki N, Shibasaki T, Kashima Y, Miki T, Takahashi K, Ueno H, et al. cAMP-GEFII is a direct target of cAMP in regulated exocytosis. Nat Cell Biol. 2000;2:805\u201311.","journal-title":"Nat Cell Biol"},{"key":"159_CR15","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nrcardio.2011.211","volume":"9","author":"J Sivertsen","year":"2012","unstructured":"Sivertsen J, Rosenmeier J, Holst JJ, Vilsb\u00f8ll T. The effect of glucagon-like peptide 1 on cardiovascular risk. Nat Rev Cardiol. 2012;9:209\u201322.","journal-title":"Nat Rev Cardiol."},{"key":"159_CR16","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1152\/ajplegacy.1938.124.2.279","volume":"124","author":"H Bergman","year":"1938","unstructured":"Bergman H, Drury DR. The relationship of kidney function to the glucose utilization of the extra abdominal tissues. Am J Physiol. 1938;124:279\u201384.","journal-title":"Am J Physiol"},{"key":"159_CR17","first-page":"332","volume":"3","author":"P Meriel","year":"1958","unstructured":"Meriel P, Galinier F, Suc J, et al. Le metabolisme duRein humaian. Rev Franc Etudes Clin Biol. 1958;3:332\u20134.","journal-title":"Rev Franc Etudes Clin Biol"},{"key":"159_CR18","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1038\/2091244a0","volume":"209","author":"H Nieth","year":"1966","unstructured":"Nieth H, Schollmeyer P. Substrate utilization of the human kidney. Nature. 1966;209:1244\u20135.","journal-title":"Nature"},{"key":"159_CR19","doi-asserted-by":"crossref","first-page":"516","DOI":"10.2337\/diab.31.6.516","volume":"31","author":"O Bj\u00f6rkman","year":"1982","unstructured":"Bj\u00f6rkman O, Felig P. Role of the kidney in the metabolism of fructose in 60-h fasted humans. Diabetes. 1982;31:516\u201320.","journal-title":"Diabetes"},{"key":"159_CR20","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1038\/2121589a0","volume":"212","author":"G Aber","year":"1966","unstructured":"Aber G, Morris L, Housley E. Gluconeogenesis by the human kidney. Nature. 1966;212:1589\u201390.","journal-title":"Nature"},{"key":"159_CR21","first-page":"F915","volume":"275","author":"C Meyer","year":"1998","unstructured":"Meyer C, Dostou J, Nadkarni V, Gerich J. Effects of physiological hyperinsulinemia on systemic, renal and hepatic substrate metabolism. Am J Physiol. 1998;275:F915\u201321.","journal-title":"Am J Physiol"},{"key":"159_CR22","first-page":"E78","volume":"276","author":"E Cersosimo","year":"1999","unstructured":"Cersosimo E, Garlick P, Ferretti J. Insulin regulation of renal glucose metabolism in humans. Am J Physiol. 1999;276:E78\u201384.","journal-title":"Am J Physiol"},{"key":"159_CR23","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1172\/JCI118314","volume":"96","author":"M Stumvoll","year":"1995","unstructured":"Stumvoll M, Chintalapudi U, Perriello G, Welle S, Gutierrez O, Gerich J. Uptake and release of glucose by the human kidney: postabsorptive rates and responses to epinephrine. J Clin Invest. 1995;96:2528\u201333.","journal-title":"J Clin Invest."},{"key":"159_CR24","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0026-0495(98)90328-6","volume":"47","author":"M Stumvoll","year":"1998","unstructured":"Stumvoll M, Meyer C, Kreider M, Perriello G, Gerich J. Effects of glucagon on renal and hepatic glutamine gluconeogenesis in normal postabsorptive humans. Metabolism. 1998;47:1227\u201332.","journal-title":"Metabolism."},{"key":"159_CR25","first-page":"347","volume":"14","author":"A Schoolwerth","year":"1988","unstructured":"Schoolwerth A, Smith B, Culpepper R. Renal gluconeogenesis. Miner Electrolyte Metab. 1988;14:347\u201361.","journal-title":"Miner Electrolyte Metab"},{"key":"159_CR26","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1152\/physrev.1986.66.2.469","volume":"66","author":"G Wirthensohn","year":"1986","unstructured":"Wirthensohn G, Guder W. Renal substrate metabolism. Physiol Rev. 1986;66:469\u201397.","journal-title":"Physiol Rev"},{"key":"159_CR27","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s11892-002-0089-z","volume":"2","author":"C Meyer","year":"2002","unstructured":"Meyer C, Gerich JE. Role of the kidney in hyperglycemia in type 2 diabetes. Curr Diab Rep. 2002;2:237\u201341.","journal-title":"Curr Diab Rep."},{"key":"159_CR28","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/nrneph.2015.38","volume":"11","author":"M Abe","year":"2015","unstructured":"Abe M, Kalantar-Zadeh K. Hemodialysis induced hypoglycemia and glucose disarrays. Nat Rev Nephrol. 2015;11:302\u201313.","journal-title":"Nat Rev Nephrol"},{"key":"159_CR29","unstructured":"U.S. Renal Data System. Incidence, prevalence, patient characteristics and treatment modalities. National Institutes of Health, National Institute of Diabetes and Kidney Diseases. In: USRDS 2011 Annual data report. Bethesda; 2011."},{"key":"159_CR30","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","volume":"352","author":"UK Prospective Diabetes Study Group","year":"1998","unstructured":"UK Prospective Diabetes Study Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes: UKPDS 34. Lancet. 1998;352:854\u201365.","journal-title":"Lancet"},{"key":"159_CR31","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJM197608192950804","volume":"295","author":"RJ Koenig","year":"1976","unstructured":"Koenig RJ, Peterson CM, Jones RL, et al. Correlation of glucose regulation and hemoglobin AIc in diabetes mellitus. N Engl J Med. 1976;295:417\u201320.","journal-title":"N Engl J Med"},{"key":"159_CR32","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1210\/jc.2011-1894","volume":"97","author":"WH Herman","year":"2012","unstructured":"Herman WH, Cohen RM. Racial and ethnic differences in the relationship between HbA1c and blood glucose: implications for the diagnosis of diabetes. J Clin Endocrinol Metab. 2012;97:1067\u201372.","journal-title":"J Clin Endocrinol Metab"},{"key":"159_CR33","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1007\/s00125-007-0789-7","volume":"50","author":"The American Diabetes Association","year":"2007","unstructured":"The American Diabetes Association, European Association for the Study of Diabetes, International Federation of Clinical Chemistry and Laboratory Medicine, International Diabetes Federation. Consensus statement on the worldwide standardization of the HbA1c measurement. Diabetologia. 2007;50:2042\u20133.","journal-title":"Diabetologia"},{"key":"159_CR34","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1373\/clinchem.2006.079756","volume":"53","author":"ES Kilpatrick","year":"2007","unstructured":"Kilpatrick ES, Rigby AS, Atkin SL. Variability in the relationship between mean plasma glucose and HbA1c: implications for the assessment of glycemic control. Clin Chem. 2007;53:897\u2013901.","journal-title":"Clin Chem"},{"key":"159_CR35","doi-asserted-by":"crossref","first-page":"838","DOI":"10.5858\/2008-132-838-SOTAIT","volume":"132","author":"WG Miller","year":"2008","unstructured":"Miller WG, Myers GL, Ashwood ER, Killeen AA, Wang E, Ehlers GW, et al. State of the art in trueness and interlaboratory harmonization for ten analytes in general clinical chemistry. Arch Pathol Lab Med. 2008;132:838\u201346.","journal-title":"Arch Pathol Lab Med"},{"key":"159_CR36","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1001\/archinte.167.14.1545","volume":"167","author":"E Selvin","year":"2007","unstructured":"Selvin E, Crainiceanu CM, Brancati FL, Coresh J. Short-term variability in measures of glycemia and implications for the classification of diabetes. Arch Intern Med. 2007;167:1545\u201351.","journal-title":"Arch Intern Med"},{"issue":"10","key":"159_CR37","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1089\/dia.2011.0054","volume":"13","author":"A Pimazoni-Netto","year":"2011","unstructured":"Pimazoni-Netto A, Rodbard D, Zanella MT. Rapid improvement of glycemic control in type 2 diabetes using weekly intensive multifactorial interventions: structured glucose monitoring, patient education, and adjustment of therapy\u2014a randomized controlled trial. Diabetes Technol Ther. 2011;13(10):997\u20131004. doi: 10.1089\/dia.2011.0054 .","journal-title":"Diabetes Technol Ther."},{"key":"159_CR38","doi-asserted-by":"crossref","first-page":"753","DOI":"10.2337\/dc07-9920","volume":"30","author":"D Nathan","year":"2007","unstructured":"Nathan D, Davidson MB, Defronzo RA, Heine RJ, Henry RR, Pratley R, American Diabetes Association, et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care. 2007;30:753\u20139.","journal-title":"Diabetes Care"},{"key":"159_CR39","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.diabres.2012.10.007","volume":"99","author":"E Lenters-Westra","year":"2013","unstructured":"Lenters-Westra E, Schindhelm RK, Bilo HJ, et al. Haemoglobin A1c: historical overview and current concepts. Diabetes Res Clin Pract. 2013;99:75\u201384.","journal-title":"Diabetes Res Clin Pract"},{"key":"159_CR40","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1053\/j.ajkd.2009.10.064","volume":"55","author":"HS Chen","year":"2010","unstructured":"Chen HS, Wu TE, Lin HD, Jap TS, Hsiao LC, Lee SH, et al. Hemoglobin A(1c) and fructosamine for assessing glycemic control in diabetic patients with CKD stages 3 and 4. Am J Kidney Dis. 2010;55:867\u201374.","journal-title":"Am J Kidney Dis"},{"key":"159_CR41","first-page":"1985","volume":"47","author":"RR Little","year":"2001","unstructured":"Little RR, Rohlfing CL, Wiedmeyer HM, Myers GL, Sacks DB, Goldstein DE. The national glycohemoglobin standardization program: a 5-year progress report. Clin Chem. 2001;47:1985\u201392.","journal-title":"Clin Chem"},{"key":"159_CR42","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1753-0407.2009.00009.x","volume":"1","author":"EJ Gallagher","year":"2009","unstructured":"Gallagher EJ, Le Roith D, Bloomgarden Z. Review of hemoglobin A(1c) in the management of diabetes. J Diabetes. 2009;1:9\u201317.","journal-title":"J Diabetes."},{"key":"159_CR43","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1744-9987.2009.00661.x","volume":"13","author":"T Uzu","year":"2009","unstructured":"Uzu T, Hatta T, Deji N, Izumiya T, Ueda H, Miyazawa I, et al. Target for glycemic control in type 2 diabetic patients on hemodialysis: effects of anemia and erythropoietin injection on hemoglobin A(1c). Ther Apher Dial. 2009;13:89\u201394.","journal-title":"Ther Apher Dial."},{"key":"159_CR44","first-page":"1","volume":"0","author":"M Speeckaert","year":"2014","unstructured":"Speeckaert M, Biesen WV, Delanghe J, Slingerland R, Wiecek A, Heaf J, The European Renal Best Practice Guideline Development Group on Diabetes in Advanced CKD, et al. Are there better alternatives than haemoglobin A1c to estimate glycaemic control in the chronic kidney disease population? Nephrol Dial Transplant. 2014;0:1\u201311.","journal-title":"Nephrol Dial Transplant"},{"key":"159_CR45","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.annepidem.2005.11.009","volume":"16","author":"T Mackenzie","year":"2006","unstructured":"Mackenzie T, Brooks B, O\u2019Connor G. Beverage intake, diabetes, and glucose control of adults in America. Ann Epidemiol. 2006;16:688\u201391.","journal-title":"Ann Epidemiol"},{"key":"159_CR46","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.2169\/internalmedicine.48.2301","volume":"48","author":"T Okada","year":"2009","unstructured":"Okada T, Nakao T, Matsumoto H, Yamanaka T, Nagaoka Y, Tamekuni T. Influence of age and nutritional status on glycated albumin values in hemodialysis patients. Intern Med. 2009;48:1495\u20139.","journal-title":"Intern Med"},{"key":"159_CR47","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2337\/diacare.26.1.163","volume":"26","author":"RM Cohen","year":"2003","unstructured":"Cohen RM, Holmes YR, Chenier TC, Joiner CH. Discordance between HbA1c and fructosamine: evidence for a glycosylation gap and its relation to diabetic nephropathy. Diabetes Care. 2003;26:163\u20137.","journal-title":"Diabetes Care"},{"key":"159_CR48","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1038\/ki.2010.193","volume":"117","author":"N Mittman","year":"2010","unstructured":"Mittman N, Desiraju B, Fazil I, Kapupara H, Chattopadhyay J, Jani CM, et al. Serum fructosamine versus glycosylated hemoglobin as an index of glycemic control, hospitalization, and infection in diabetic hemodialysis patients. Kidney Int Suppl. 2010;117:S41\u20135.","journal-title":"Kidney Int Suppl"},{"key":"159_CR49","doi-asserted-by":"crossref","first-page":"S261","DOI":"10.1016\/0168-8227(94)90259-3","volume":"24","author":"T Yamanouchi","year":"1994","unstructured":"Yamanouchi T, Akanuma Y. Serum 1,5-anhydroglucitol (1,5 AG): new clinical marker for glycemic control. Diabetes Res Clin Pract. 1994;24:S261\u20138.","journal-title":"Diabetes Res Clin Pract"},{"key":"159_CR50","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.clinbiochem.2008.08.086","volume":"42","author":"CL Nerby","year":"2009","unstructured":"Nerby CL, Stickle DF. 1,5-anhydroglucitol monitoring in diabetes: a mass balance perspective. Clin Biochem. 2009;42:158\u201367.","journal-title":"Clin Biochem"},{"key":"159_CR51","doi-asserted-by":"crossref","first-page":"708","DOI":"10.2337\/db11-1015","volume":"61","author":"J Ricks","year":"2012","unstructured":"Ricks J, Molnar MZ, Kovesdy CP, Shah A, Nissenson AR, Williams M, et al. Glycemic control and cardiovascular mortality in hemodialysis patients with diabetes: a 6-year cohort study. Diabetes. 2012;61:708\u201315.","journal-title":"Diabetes"},{"key":"159_CR52","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2013.06.020","volume":"63","author":"CJ Hill","year":"2014","unstructured":"Hill CJ, Maxwell AP, Cardwell CR, Freedman BI, Tonelli M, Emoto M, et al. Glycated hemoglobin and risk of death in diabetic patients treated with hemodialysis: a meta-analysis. Am J Kidney Dis. 2014;63:84\u201394.","journal-title":"Am J Kidney Dis"},{"key":"159_CR53","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0272-6386(12)80985-1","volume":"23","author":"DM Spiegel","year":"1994","unstructured":"Spiegel DM, Breyer JA. Serum albumin: a predictor of long-term outcome in peritoneal dialysis patients. Am J Kidney Dis. 1994;23:283\u20135.","journal-title":"Am J Kidney Dis"},{"key":"159_CR54","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.2337\/dc12-0027","volume":"35","author":"BI Freedman","year":"2012","unstructured":"Freedman BI. A critical evaluation of glycated protein parameters in advanced nephropathy: a matter of life or death: time to dispense with the hemoglobin A1C in end-stage kidney disease. Diabetes Care. 2012;35:1621\u20134.","journal-title":"Diabetes Care"},{"key":"159_CR55","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.cca.2012.12.022","volume":"418","author":"RR Little","year":"2013","unstructured":"Little RR, Rohlfing CL, Tennill AL, Hanson SE, Connolly S, Higgins T, et al. Measurement of Hba(1C) in patients with chronic renal failure. Clin Chim Acta. 2013;418:73\u20136.","journal-title":"Clin Chim Acta"},{"issue":"9131","key":"159_CR56","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","volume":"352","author":"UK Prospective Diabetes Study","year":"1998","unstructured":"UK Prospective Diabetes Study. UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33. Lancet. 1998;352(9131):837\u201353.","journal-title":"Lancet"},{"key":"159_CR57","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","volume":"329","author":"The Diabets Control and Complications Trial Resesarch Group","year":"1993","unstructured":"The Diabets Control and Complications Trial Resesarch Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977\u201386.","journal-title":"N Engl J Med"},{"key":"159_CR58","first-page":"147","volume":"2013\u20132014","author":"SB Diabetes de","year":"2014","unstructured":"de Diabetes SB. Diretrizes da Sociedade Brasileira de. Diabetes. 2014;2013\u20132014:147\u201365.","journal-title":"Diabetes"},{"issue":"Suppl 1","key":"159_CR59","doi-asserted-by":"publisher","first-page":"S88","DOI":"10.2337\/dc15-S018","volume":"38","author":"RW Grant","year":"2015","unstructured":"Grant RW, Donner TW, Fradkin JE, et al. Professional practice committee for the standards of medical care in diabetes-2015. Diabetes Care. 2015;38(Suppl 1):S88\u20139. doi: 10.2337\/dc15-S018 .","journal-title":"Diabetes Care"},{"key":"159_CR60","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","volume":"358","author":"HC Gerstein","year":"2008","unstructured":"Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC, Bigger JT, et al. Effects of intensive glucose lowering in type 2 diabetes. New Engl J Med. 2008;358:2545\u201359.","journal-title":"New Engl J Med."},{"issue":"5","key":"159_CR61","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/archinternmed.2011.16","volume":"171","author":"AR Gosmanov","year":"2011","unstructured":"Gosmanov AR, Gosmanova EO. Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the DCCT\/EDIC cohort. Arch Intern Med. 2011;171(5):412\u201320.","journal-title":"Arch Intern Med"},{"key":"159_CR62","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1056\/NEJMoa021835","volume":"348","author":"BA Perkins","year":"2003","unstructured":"Perkins BA, Ficociello LH, Silva KH, Finkelstein DM, Warram JH, Krolewski AS. Regression of microalbuminuria in type 1 diabetes. N Engl J Med. 2003;348:2285\u201393.","journal-title":"N Engl J Med"},{"issue":"24","key":"159_CR63","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","volume":"358","author":"A Patel","year":"2008","unstructured":"ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560\u201372. doi: 10.1056\/NEJMoa0802987 .","journal-title":"N Engl J Med"},{"issue":"2","key":"159_CR64","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1172\/JCI110067","volume":"67","author":"RA DeFronzo","year":"1981","unstructured":"DeFronzo RA, Alvestrand A, Smith D, Hendler R, Hendler E, Wahren J. Insulin resistance in uremia. J Clin Invest. 1981;67(2):563\u20138. doi: 10.1172\/JCI110067 .","journal-title":"J Clin Invest."},{"issue":"5","key":"159_CR65","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1038\/ki.1992.414","volume":"42","author":"HJ Adrogu\u00e9","year":"1992","unstructured":"Adrogu\u00e9 HJ. Glucose homeostasis and the kidney. Kidney Int. 1992;42(5):1266\u201382. doi: 10.1038\/ki.1992.414 .","journal-title":"Kidney Int"},{"key":"159_CR66","unstructured":"Charpentier G, Riveline JP, Varroud-Vial M. Management of drugs affecting blood glucose in diabetic patients with renal failure. Diabetes Metab. 2000;26(4):73\u201385. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/10922977 ."},{"key":"159_CR67","doi-asserted-by":"crossref","unstructured":"Carone FA, Peterson DR. Hydrolysis and transport of small peptides by the proximal tubule. Am J Physiol. 1980;238(3):F151\u20138. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/6989268 .","DOI":"10.1152\/ajprenal.1980.238.3.F151"},{"key":"159_CR68","doi-asserted-by":"crossref","unstructured":"Mak RH, DeFronzo RA. Glucose and insulin metabolism in uremia. Nephron. 1992;61(4):377\u201382. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/1501732 .","DOI":"10.1159\/000186953"},{"issue":"2","key":"159_CR69","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/j.1525-139X.2010.00700.x","volume":"23","author":"RZ Alicic","year":"2010","unstructured":"Alicic RZ, Tuttle KR. Management of the diabetic patient with advanced chronic kidney disease. Semin Dial. 2010;23(2):140\u20137. doi: 10.1111\/j.1525-139X.2010.00700.x .","journal-title":"Semin Dial"},{"issue":"2 Suppl 2","key":"159_CR70","doi-asserted-by":"publisher","first-page":"S22","DOI":"10.1053\/j.ajkd.2013.10.049","volume":"63","author":"ME Williams","year":"2014","unstructured":"Williams ME, Garg R. Glycemic management in ESRD and earlier stages of CKD. Am J Kidney Dis. 2014;63(2 Suppl 2):S22\u201338. doi: 10.1053\/j.ajkd.2013.10.049 .","journal-title":"Am J Kidney Dis"},{"key":"159_CR71","doi-asserted-by":"crossref","unstructured":"Amico JA, Klein I. Diabetic management in patients with renal failure. Diabetes Care. 1981;4(3):430\u20134. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/10922977 .","DOI":"10.2337\/diacare.4.3.430"},{"key":"159_CR72","doi-asserted-by":"crossref","unstructured":"M\u00fchlhauser I, Toth G, Sawicki PT, Berger M. Severe hypoglycemia in type I diabetic patients with impaired kidney function. Diabetes Care. 1991;14(4):344\u20136. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/2060440 .","DOI":"10.2337\/diacare.14.4.344"},{"issue":"13","key":"159_CR73","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1001\/archinte.161.13.1653","volume":"161","author":"CD Miller","year":"2001","unstructured":"Miller CD, Phillips LS, Ziemer DC, Gallina DL, Cook CB, El-Kubbi IM. Hypoglycemia in patients with type 2 diabetes mellitus. Arch Intern Med. 2001;161(13):1653\u20139. doi: 10.1001\/archinte.161.13.1653 .","journal-title":"Arch Intern Med"},{"issue":"6","key":"159_CR74","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1111\/j.1523-1755.2005.00365.x","volume":"67","author":"AS Levey","year":"2005","unstructured":"Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, et al. Definition and classification of chronic kidney disease: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int. 2005;67(6):2089\u2013100. doi: 10.1111\/j.1523-1755.2005.00365.x .","journal-title":"Kidney Int"},{"key":"159_CR75","doi-asserted-by":"crossref","unstructured":"Bode BW, Gross TM, Thornton KR, Mastrototaro JJ. Continuous glucose monitoring used to adjust diabetes therapy improves glycosylated hemoglobin: a pilot study. Diabetes Res Clin Pract. 1999;46(3):183\u201390. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/10624783 .","DOI":"10.1016\/S0168-8227(99)00113-8"},{"issue":"3","key":"159_CR76","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/ki.2013.243","volume":"84","author":"KM Andrassy","year":"2013","unstructured":"Andrassy KM. Comments on \u2018KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease\u2019. Kidney Int. 2013;84(3):622\u20133.","journal-title":"Kidney Int"},{"issue":"362","key":"159_CR77","first-page":"1575","volume":"29","author":"WC Cushman","year":"2010","unstructured":"ACCORD study group, Cushman WC, Evans GW, Byington RP, Goff DC, Grimm RH, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;29(362):1575\u201385.","journal-title":"N Engl J Med"},{"issue":"6656","key":"159_CR78","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1136\/bmj.297.6656.1086","volume":"297","author":"H Parving","year":"1988","unstructured":"Parving H, Hommel E, Smidt UM. Protection of kidney function and decrease in albuminuria by captopril in insulin dependent diabetics with nephropathy. BMJ. 1988;297(6656):1086\u201391.","journal-title":"BMJ"},{"issue":"5","key":"159_CR79","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1001\/jama.2013.284427","volume":"311","author":"PA James","year":"2014","unstructured":"James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507\u201320. doi: 10.1001\/jama.2013.284427 .","journal-title":"JAMA"},{"issue":"20","key":"159_CR80","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","volume":"369","author":"LF Fried","year":"2013","unstructured":"Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med. 2013;369(20):1892\u2013903. doi: 10.1056\/NEJMoa1303154 .","journal-title":"N Engl J Med"},{"issue":"9982","key":"159_CR81","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/S0140-6736(14)62459-4","volume":"385","author":"C PalmerSuetonia","year":"2015","unstructured":"PalmerSuetonia C, et al. Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis. Lancet. 2015;385(9982):2047\u201356.","journal-title":"Lancet"},{"issue":"21","key":"159_CR82","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1001\/jama.290.21.2805","volume":"290","author":"CJ Pepine","year":"2003","unstructured":"Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril study (INVEST): a randomized controlled trial. JAMA. 2003;290(21):2805\u201316. doi: 10.1001\/jama.290.21.2805 .","journal-title":"JAMA"},{"issue":"12","key":"159_CR83","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/nrendo.2013.184","volume":"9","author":"D Fineberg","year":"2013","unstructured":"Fineberg D, Jandeleit-Dahm KA, Cooper ME. Diabetic nephropathy: diagnosis and treatment. Nat Rev Endocrinol. 2013;9(12):713\u201323.","journal-title":"Nat Rev Endocrinol."},{"issue":"3","key":"159_CR84","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/kisup.2013.27","volume":"3","author":"KDIGO","year":"2013","unstructured":"KDIGO. Clinical practice guideline for lipid management in chronic kidney disease. Kidney Inter. 2013;3(3):259\u2013305.","journal-title":"Kidney Inter."},{"issue":"3","key":"159_CR85","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1053\/j.ajkd.2014.10.005","volume":"65","author":"MJ Sarnak","year":"2015","unstructured":"Sarnak MJ, Bloom R, Muntner P, Rahman M, Saland JM, Wilson PW, et al. KDOQI US commentary on the 2013 KDIGO clinical practice guideline for lipid management in CKD. Am J Kidney Dis. 2015;65(3):354\u201366. doi: 10.1053\/j.ajkd.2014.10.005 .","journal-title":"Am J Kidney Dis"},{"issue":"Suppl 1","key":"159_CR86","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.2337\/dc14-S014","volume":"37","author":"American Diabetes Association","year":"2014","unstructured":"American Diabetes Association. Standards of medical care in diabetes\u20142014. Diabetes Care. 2014;37(Suppl 1):S14\u201380. doi: 10.2337\/dc14-S014 .","journal-title":"Diabetes Care"},{"issue":"6","key":"159_CR87","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1111\/j.1463-1326.2007.00670.x","volume":"9","author":"AJ Krentz","year":"2007","unstructured":"Krentz AJ, Clough G, Byrne CD. Interactions between microvascular and macrovascular disease in diabetes: pathophysiology and therapeutic implications. Diabetes Obes Metab. 2007;9(6):781\u201391. doi: 10.1111\/j.1463-1326.2007.00670.x .","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"159_CR88","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.2337\/dc12-2327","volume":"36","author":"T Moriya","year":"2013","unstructured":"Moriya T, Tanaka S, Kawasaki R, Ohashi Y, Akanuma Y, Yamada N, Japan Diabetes Complications Study, et al. Diabetic retinopathy and microalbuminuria can predict macroalbuminuria and renal function decline in Japanese type 2 diabetic patients. Diabetes Care. 2013;36(9):2803\u20139. doi: 10.2337\/dc12-2327 .","journal-title":"Diabetes Care"},{"issue":"2","key":"159_CR89","doi-asserted-by":"crossref","first-page":"527","DOI":"10.2337\/diabetes.54.2.527","volume":"54","author":"R Klein","year":"2005","unstructured":"Klein R, Zinman B, Gardiner R, Suissa S, Donnellly SM, Sinaiko AR, et al. The relationship of diabetic retinopathy to preclinical diabetic glomerulopathy lesions in type 1 diabetic patients. Diabetes. 2005;54(2):527\u201333.","journal-title":"Diabetes"},{"issue":"7","key":"159_CR90","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1111\/j.1464-5491.2007.02145.x","volume":"24","author":"PCY Tong","year":"2007","unstructured":"Tong PCY, Kong AP, So WY, Yang X, Ng MCY, Ho CS, et al. Interactive effect of retinopathy and macroalbuminuria on all-cause mortality, cardiovascular and renal end points in Chinese patients with type 2 diabetes mellitus. Diabet Med. 2007;24(7):741\u20136. doi: 10.1111\/j.1464-5491.2007.02145.x .","journal-title":"Diabet Med"},{"issue":"2","key":"159_CR91","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1053\/ajkd.2002.30549","volume":"39","author":"MS Joy","year":"2002","unstructured":"Joy MS, Cefalu WT, Hogan SL, Nachman PH. Long-term glycemic control measurements in diabetic patients receiving hemodialysis. Am J Kidney Dis. 2002;39(2):297\u2013307. doi: 10.1053\/ajkd.2002.30549 .","journal-title":"Am J Kidney Dis"},{"issue":"193","key":"159_CR92","first-page":"95","volume":"49","author":"DJ Ewing","year":"1980","unstructured":"Ewing DJ, Campbell IW, Clarke BF. The natural history of diabetic autonomic neuropathy. Q J Med. 1980;49(193):95\u2013108.","journal-title":"Q J Med."},{"issue":"7","key":"159_CR93","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1002\/dmrr.1239","volume":"27","author":"V Spallone","year":"2011","unstructured":"Spallone V, Ziegler D, Freeman R, Bernardi L, Frontoni S, Pop-Busui R, et al. Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management. Diabetes Metab Res Rev. 2011;27(7):639\u201353. doi: 10.1002\/dmrr.1239 .","journal-title":"Diabetes Metab Res Rev."},{"issue":"6","key":"159_CR94","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1007\/s00125-014-3211-2","volume":"57","author":"AA Tahrani","year":"2014","unstructured":"Tahrani AA, Dubb K, Raymond NT, Begum S, Altaf QA, Sadiqi H, et al. Cardiac autonomic neuropathy predicts renal function decline in patients with type 2 diabetes: a cohort study. Diabetologia. 2014;57(6):1249\u201356. doi: 10.1007\/s00125-014-3211-2 .","journal-title":"Diabetologia"},{"issue":"5","key":"159_CR95","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1053\/j.ajkd.2012.07.005","volume":"60","author":"National Kidney Foundation","year":"2012","unstructured":"National Kidney Foundation. KDOQI clinical practice guideline for diabetes and CKD: 2012 update. Am J Kidney Dis. 2012;60(5):850\u201386. doi: 10.1053\/j.ajkd.2012.07.005 .","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"159_CR96","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1590\/S0004-27302008000200028","volume":"52","author":"MC Foss-Freitas","year":"2008","unstructured":"Foss-Freitas MC, MarquesJunior W, Foss MC. Autonomic neuropathy: a high risk complication for type 1 diabetes mellitus. Arq Bras Endrocrinol Metab. 2008;52(2):398\u2013406.","journal-title":"Arq Bras Endrocrinol Metab."},{"key":"159_CR97","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1186\/2193-1801-3-549","volume":"3","author":"F Arrellano-Valdez","year":"2014","unstructured":"Arrellano-Valdez F, Urrutia-Osorio M, Arroyo C, Soto-Vega E. A comprehensive review of urologic complications in patients with diabetes. Springerplus. 2014;3:549. doi: 10.1186\/2193-1801-3-549 .","journal-title":"Springerplus."},{"issue":"2","key":"159_CR98","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/ki.1981.22","volume":"19","author":"WR Procci","year":"1981","unstructured":"Procci WR, Goldstein DA, Adelstein J, Massry SG. Sexual dysfunction in the male patient with uremia: a reappraisal. Kidney Int. 1981;19(2):317\u201323.","journal-title":"Kidney Int"},{"issue":"5","key":"159_CR99","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.2337\/diacare.26.5.1553","volume":"26","author":"AI Vinik","year":"2003","unstructured":"Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care. 2003;26(5):1553\u201379.","journal-title":"Diabetes Care"},{"issue":"6","key":"159_CR100","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.2337\/diacare.27.6.1454","volume":"27","author":"C C\u00e1rdenas","year":"2004","unstructured":"C\u00e1rdenas C, Bordiu E, Bagazoitia J, Calle-Pascual AL, Diabetes and Nutrition Study Group, Spanish Diabetes Association. Polyunsaturated fatty acid consumption may play role in the onset and regression of microalbumin\u00faria in well-controlled type 1 and type 2 diabetic people: a 7-year, prospective, population-based, observational multicenter study. Diabetes Care. 2004;27(6):1454\u20137.","journal-title":"Diabetes Care"},{"issue":"4","key":"159_CR101","doi-asserted-by":"crossref","first-page":"663","DOI":"10.2337\/diacare.25.4.663","volume":"25","author":"CA Houlihan","year":"2002","unstructured":"Houlihan CA, Allen TJ, Baxter AL, Panangiotopoulos S, Casley DJ, Cooper ME, et al. A low-sodium diet potentiates the effects of losartan in type 2 diabetes. Diabetes Care. 2002;25(4):663\u201371.","journal-title":"Diabetes Care"},{"issue":"6","key":"159_CR102","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.2215\/CJN.00800209","volume":"4","author":"MF Moen","year":"2009","unstructured":"Moen MF, Zhan M, Hsu VD, Walker LD, Einhorn LM, Seliger SL, et al. Frequency of hypoglycemia and its significance in chronic kidney disease. Clin J Am Soc Nephrol. 2009;4(6):1121\u20137.","journal-title":"Clin J Am Soc Nephrol."},{"issue":"1","key":"159_CR103","first-page":"34","volume":"34","author":"R G\u00f3mez-Huelgas","year":"2014","unstructured":"G\u00f3mez-Huelgas R, Mart\u00ednez-Castelao A, Artola S, G\u00f3rriz JL, Men\u00e9ndez E. Consensus document on treatment of type 2 diabetes in patients with chronic kidney diseases. Nefrologia. 2014;34(1):34\u201345.","journal-title":"Nefrologia"},{"issue":"1","key":"159_CR104","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.mcna.2012.11.001","volume":"97","author":"R Garg","year":"2013","unstructured":"Garg R, Williams ME. Diabetes management in the kidney patient. Med Clin North Am. 2013;97(1):135\u201356.","journal-title":"Med Clin North Am"},{"issue":"7258","key":"159_CR105","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","volume":"321","author":"IM Stratton","year":"2000","unstructured":"Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405\u201312.","journal-title":"BMJ"},{"issue":"2","key":"159_CR106","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa0808431","volume":"360","author":"W Duckworth","year":"2009","unstructured":"Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129\u201339.","journal-title":"N Engl J Med"},{"issue":"21","key":"159_CR107","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1001\/archinternmed.2011.537","volume":"171","author":"S Shurraw","year":"2011","unstructured":"Shurraw S, Hemmelgarn B, Lin M, Sr Majumdar, Klarenbach S, Manns B, et al. Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease: a population-based cohort study. Arch Intern Med. 2011;171(21):1920\u20137.","journal-title":"Arch Intern Med"},{"issue":"5","key":"159_CR108","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.2215\/CJN.09291010","volume":"6","author":"JM Lachin","year":"2011","unstructured":"Lachin JM, Viberti G, Zinman B, Haffner SM, Aftring RP, Paul G, et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clin J Am Soc Nephrol. 2011;6(5):1032\u201340.","journal-title":"Clin J Am Soc Nephrol."},{"issue":"5","key":"159_CR109","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1093\/clinchem\/48.5.784","volume":"48","author":"RR Little","year":"2002","unstructured":"Little RR, Tennill AL, Rohlfing C, Wiedmeyer HM, Khanna R, Goel S, et al. Can glycohemoglobin be used to assess glycemic control in patients with chronic renal failure? Clin Chem. 2002;48(5):784\u20136.","journal-title":"Clin Chem"},{"issue":"Suppl 1","key":"159_CR110","first-page":"S11","volume":"35","author":"American Diabetes Association","year":"2012","unstructured":"American Diabetes Association. Standards of medical care in diabetes\u20142012. Diabetes Care. 2012;35(Suppl 1):S11\u201363.","journal-title":"Diabetes Care"},{"issue":"1","key":"159_CR111","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1463-1326.2006.00657.x","volume":"10","author":"S Runge","year":"2008","unstructured":"Runge S, Mayerle J, Warnke C, Robinson D, Roser M, Felix SB, et al. Metformin-associated lactic acidosis in patients with renal impairment solely due to drug accumulation? Diabetes Obes Metab. 2008;10(1):91\u20133.","journal-title":"Diabetes Obes Metab"},{"key":"159_CR112","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.2337\/dc10-2361","volume":"34","author":"KJ Lipska","year":"2011","unstructured":"Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mild-tomoderate renal insufficiency. Diabetes Care. 2011;34:1431\u20137.","journal-title":"Diabetes Care"},{"key":"159_CR113","doi-asserted-by":"crossref","first-page":"c380","DOI":"10.1159\/000323739","volume":"118","author":"HJ Nye","year":"2011","unstructured":"Nye HJ, Herrington WG. Metformin: the safest hypoglycaemic agent in chronic kidney disease? Nephron Clin Pract. 2011;118:c380\u20133.","journal-title":"Nephron Clin Pract."},{"issue":"2","key":"159_CR114","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00228-003-0592-4","volume":"59","author":"A Holstein","year":"2003","unstructured":"Holstein A, Plaschke A, Hammer C, Egberts EH. Characteristics and time course of severe glimepiride-versus glibenclamide induced hypoglycaemia. Eur J Clin Pharmacol. 2003;59(2):91\u20137.","journal-title":"Eur J Clin Pharmacol"},{"key":"159_CR115","doi-asserted-by":"crossref","first-page":"886","DOI":"10.2337\/diacare.26.3.886","volume":"26","author":"C Hasslacher","year":"2003","unstructured":"Hasslacher C, Multinational Repaglinide Renal Study Group. Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function. Diabetes Care. 2003;26:886\u201391.","journal-title":"Diabetes Care"},{"issue":"24","key":"159_CR116","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","volume":"356","author":"SE Nissen","year":"2007","unstructured":"Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457\u201371.","journal-title":"N Engl J Med"},{"issue":"5","key":"159_CR117","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1681\/ASN.2008060579","volume":"20","author":"SP Ramirez","year":"2009","unstructured":"Ramirez SP, Albert JM, Blayney MJ, Tentori F, Goodkin DA, Wolfe RA, et al. Rosiglitazone is associated with mortality in chronic hemodialysis patients. J Am Soc Nephrol. 2009;20(5):1094\u2013101.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"159_CR118","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1345\/aph.1G336","volume":"40","author":"SH Hsiao","year":"2006","unstructured":"Hsiao SH, Liao LH, Cheng PN, Wu TJ. Hepatotoxicity associated with acarbose therapy. Ann Pharmacother. 2006;40(1):151\u20134.","journal-title":"Ann Pharmacother"},{"key":"159_CR119","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1038\/ki.2010.509","volume":"120","author":"A Mather","year":"2011","unstructured":"Mather A, Pollock C. Glucose handling by the kidney. Kidney Int Suppl. 2011;120:S1\u20136.","journal-title":"Kidney Int Suppl"},{"issue":"2","key":"159_CR120","doi-asserted-by":"crossref","first-page":"9417","DOI":"10.1136\/bmjopen-2015-009417","volume":"6","author":"DS Shyangdan","year":"2016","unstructured":"Shyangdan DS, Uthman OA, Waugh N. SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis. BMJ Open. 2016;6(2):9417.","journal-title":"BMJ Open."},{"issue":"3","key":"159_CR121","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1016\/j.diabres.2013.11.014","volume":"103","author":"D Dubois-Laforgue","year":"2014","unstructured":"Dubois-Laforgue D, Boutboul D, L\u00e9vy DJ, Joly D, Timsit J. Severe acute renal failure in patients treated with glucagon-like peptide-1 receptor agonists. Diabetes Res Clin Pract. 2014;103(3):e53\u20135.","journal-title":"Diabetes Res Clin Pract"},{"issue":"7","key":"159_CR122","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/j.1463-1326.2008.00914.x","volume":"10","author":"JC Chan","year":"2008","unstructured":"Chan JC, Scott R, Arjona Ferreira JC, Sheng D, Gonzalez E, Davies MJ, et al. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes Metab. 2008;10(7):545\u201355.","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"159_CR123","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1111\/j.1463-1326.2011.01458.x","volume":"13","author":"U Graefe-Mody","year":"2011","unstructured":"Graefe-Mody U, Friedrich C, Port A, Ring A, Retlich S, Heise T, et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin(*). Diabetes Obes Metab. 2011;13(10):939\u201346.","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"159_CR124","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/j.1463-1326.2011.01467.x","volume":"13","author":"V Lukashevich","year":"2011","unstructured":"Lukashevich V, Schweizer A, Shao Q, Groop PH, Kothny W. Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial. Diabetes Obes Metab. 2011;13(10):947\u201354.","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"159_CR125","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1111\/j.1742-1241.2011.02812.x","volume":"65","author":"M Nowicki","year":"2011","unstructured":"Nowicki M, Rychlik I, Haller H, Warren M, Suchower L, gause-Nilsson I, et al. Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study. Int J Clin Pract. 2011;65(12):1230\u20139.","journal-title":"Int J Clin Pract"},{"issue":"6","key":"159_CR126","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1463-1326.2011.01382.x","volume":"13","author":"M Nowicki","year":"2011","unstructured":"Nowicki M, Rychlik I, Haller H, Warren ML, Suchower L, Gause-Nilsson I, D1680C00007 Investigators. Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment. Diabetes Obes Metab. 2011;13(6):523\u201332.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"159_CR127","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/BF00304849","volume":"27","author":"R Rabkin","year":"1984","unstructured":"Rabkin R, Ryan MP, Duckworth WC. The renal metabolism of insulin. Diabetologia. 1984;27(3):351\u20137.","journal-title":"Diabetologia"},{"issue":"2","key":"159_CR128","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1210\/edrv-2-2-210","volume":"2","author":"WC Duckworth","year":"1981","unstructured":"Duckworth WC, Kitabchi AE. Insulin metabolism and degradation. Endocr Rev. 1981;2(2):210\u201333.","journal-title":"Endocr Rev"},{"issue":"3","key":"159_CR129","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1210\/edrv-9-3-319","volume":"9","author":"WC Duckworth","year":"1988","unstructured":"Duckworth WC. Insulin degradation: mechanisms, products, and significance. Endocr Rev. 1988;9(3):319\u201345.","journal-title":"Endocr Rev"},{"issue":"10","key":"159_CR130","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/j.1463-1326.2007.00802.x","volume":"10","author":"P Iglesias","year":"2008","unstructured":"Iglesias P, D\u00edez JJ. Insulin therapy in renal disease. Diabetes Obes Metab. 2008;10(10):811\u201323.","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"159_CR131","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.metabol.2005.01.028","volume":"54","author":"JA Charlesworth","year":"2005","unstructured":"Charlesworth JA, Kriketos AD, Jones JE, Erlich JH, Campbell LV, Peake PW. Insulin resistance and postprandial triglyceride levels in primary renal disease. Metabolism. 2005;54(6):821\u20138.","journal-title":"Metabolism."},{"issue":"3","key":"159_CR132","doi-asserted-by":"crossref","first-page":"214","DOI":"10.3810\/pgm.2013.05.2672","volume":"125","author":"JS Freeman","year":"2013","unstructured":"Freeman JS. Review of insulin-dependent and insulin-independent agents for treating patients with type 2 diabetes mellitus and potential role for sodium-glucose co-transporter 2 inhibitors. Postgrad Med. 2013;125(3):214\u201326.","journal-title":"Postgrad Med"},{"issue":"04","key":"159_CR133","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4172\/2155-6156.1000189","volume":"03","author":"M Niafar","year":"2012","unstructured":"Niafar M, Nakhjavani M. Efficacy and safety of insulin glargine in type 2 diabetic patients with renal failure. J Diabetes Metab. 2012;03(04):1\u20134.","journal-title":"J Diabetes Metab."},{"key":"159_CR134","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.2337\/dc12-0578","volume":"35","author":"D Baldwin","year":"2012","unstructured":"Baldwin D, Lee H, Zander J, Emanuele MA, Munoz C, Glossop V, et al. A randomized trial of two weight-based doses of insulin glargine and glulisine in hospitalized subjects with type 2 diabetes and renal insufficiency. Diabetes Care. 2012;35:1970\u20134.","journal-title":"Diabetes Care"},{"issue":"24","key":"159_CR135","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.2146\/ajhp060102","volume":"63","author":"MC Jones","year":"2006","unstructured":"Jones MC, Patel M. Insulin detemir: a long-acting insulin product. Am J Health Syst Pharm. 2006;63(24):2466\u201372.","journal-title":"Am J Health Syst Pharm"},{"key":"159_CR136","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.2337\/dc07-0002","volume":"30","author":"F Porcellati","year":"2007","unstructured":"Porcellati F, Rossetti P, Busciantella NR, Marzotti S, Lucidi P, Luzio S, et al. Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study. Diabetes Care. 2007;30:2447\u201352.","journal-title":"Diabetes Care"},{"issue":"4","key":"159_CR137","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/2042018813501188","volume":"4","author":"F Kulozik","year":"2013","unstructured":"Kulozik F, Hasslacher C. Insulin requirements in patients with diabetes and declining kidney function: differences between insulin analogues and human insulin? Ther Adv Endocrinol Metab. 2013;4(4):113\u201321.","journal-title":"Ther Adv Endocrinol Metab."},{"issue":"2","key":"159_CR138","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s40262-013-0113-2","volume":"53","author":"I Kiss","year":"2014","unstructured":"Kiss I, Arold G, Roepstorff C, B\u00f8ttcher SG, Klim S, Haahr H. Insulin degludec: pharmacokinetics in patients with renal impairment. Clin Pharmacokinet. 2014;53(2):175\u201383.","journal-title":"Clin Pharmacokinet"},{"key":"159_CR139","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.clinthera.2007.12.013","volume":"29","author":"BW Bode","year":"2007","unstructured":"Bode BW. Use of rapid-acting insulin analogues in the treatment of patients with type 1 and type 2 diabetes mellitus: insulin pump therapy versus multiple daily injections. Clin Ther. 2007;29:135\u201344.","journal-title":"Clin Ther"},{"issue":"2","key":"159_CR140","doi-asserted-by":"crossref","first-page":"502","DOI":"10.2337\/diacare.26.2.502","volume":"26","author":"P Ruggenenti","year":"2003","unstructured":"Ruggenenti P, Flores C, Aros C, Ene-Iordache B, Trevisan R, Ottomano C, et al. Renal and metabolic effects of insulin lispro in type 2 diabetic subjects with overt nephropathy. Diabetes Care. 2003;26(2):502\u20139.","journal-title":"Diabetes Care"},{"issue":"2","key":"159_CR141","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/ndt\/gfi205","volume":"21","author":"A Ersoy","year":"2006","unstructured":"Ersoy A, Ersoy C, Altinay T. Insulin analogue usage in a haemodialysis patient with type 2 diabetes mellitus. Nephrol Dial Transplant. 2006;21(2):553\u20134.","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"159_CR142","doi-asserted-by":"crossref","first-page":"492","DOI":"10.5414\/CPP41492","volume":"41","author":"D Czock","year":"2003","unstructured":"Czock D, Aisenpreis U, Rasche FM, Jehle PM. Pharmacokinetics and pharmacodynamics of lispro-insulin in hemodialysis patients with diabetes mellitus. Int J Clin Pharmacol Ther. 2003;41(10):492\u20137.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"2","key":"159_CR143","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1053\/j.jrn.2014.07.011","volume":"25","author":"H Urata","year":"2015","unstructured":"Urata H, Mori K, Emoto M, Yamazaki Y, Motoyama K, Morioka T, et al. Advantage of insulin glulisine over regular insulin in patients with type 2 diabetes and severe renal insufficiency. J Ren Nutr. 2015;25(2):129\u201334.","journal-title":"J Ren Nutr."},{"issue":"5","key":"159_CR144","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1365-2125.2005.02476.x","volume":"60","author":"G Holmes","year":"2005","unstructured":"Holmes G, Galitz L, Hu P, Lyness W. Pharmacokinetics of insulin aspart in obesity, renal impairment, or hepatic impairment. Br J Clin Pharmacol. 2005;60(5):469\u201376.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"159_CR145","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1053\/j.ajkd.2007.08.012","volume":"50","author":"ND Lubowsky","year":"2007","unstructured":"Lubowsky ND, Siegel R, Pittas AG. Management of glycemia in patients with diabetes mellitus and CKD. Am J Kidney Dis. 2007;50(5):865\u201379.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"159_CR146","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2337\/dc12-2182","volume":"36","author":"WT Cefalu","year":"2012","unstructured":"Cefalu WT. Diabetes care: \u201cstate of the union\u201d. Diabetes Care. 2012;36(1):1\u20133.","journal-title":"Diabetes Care"},{"issue":"12","key":"159_CR147","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.2337\/dc12-0573","volume":"35","author":"SPB Ramirez","year":"2012","unstructured":"Ramirez SPB, McCullough KP, Thumma JR, Nelson RG, Morgenstern H, Gillespie BW, et al. Hemoglobin A(1c) levels and mortality in the diabetic hemodialysis population: findings from the Dialysis Outcomes and practice patterns study (DOPPS). Diabetes Care. 2012;35(12):2527\u201332.","journal-title":"Diabetes Care"},{"issue":"2","key":"159_CR148","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/sdi.12198","volume":"27","author":"CM Rhee","year":"2014","unstructured":"Rhee CM, Leung AM, Kovesdy CP, Lynch KE, Brent GA, Kalantar-Zadeh K. Updates on the management of diabetes in dialysis patients. Semin Dial. 2014;27(2):135\u201345.","journal-title":"Semin Dial"}],"container-title":["Diabetology &amp; Metabolic Syndrome"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-016-0159-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T10:30:34Z","timestamp":1718706634000},"score":1,"resource":{"primary":{"URL":"http:\/\/dmsjournal.biomedcentral.com\/articles\/10.1186\/s13098-016-0159-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,28]]},"references-count":148,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["159"],"URL":"https:\/\/doi.org\/10.1186\/s13098-016-0159-z","relation":{},"ISSN":["1758-5996"],"issn-type":[{"value":"1758-5996","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,28]]},"article-number":"50"}}